Esperion Therapeutics Inc (NASDAQ: ESPR) kicked off on Tuesday, up 6.09% from the previous trading day, before settling in for the closing price of $1.15. Over the past 52 weeks, ESPR has traded in a range of $0.69-$3.94.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 40.11% annually for the last half of the decade. While this was happening, its average annual earnings per share was recorded 25.51%. With a float of $194.63 million, this company’s outstanding shares have now reached $196.66 million.
In an organization with 304 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 65.3%, operating margin of -15.4%, and the pretax margin is -59.03%.
Esperion Therapeutics Inc (ESPR) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Drug Manufacturers – Specialty & Generic Industry. The insider ownership of Esperion Therapeutics Inc is 1.80%, while institutional ownership is 57.45%. The most recent insider transaction that took place on Jul 17 ’25, was worth 1,470. In this transaction General Counsel of this company sold 1,304 shares at a rate of $1.13, taking the stock ownership to the 399,937 shares. Before that another transaction happened on Jul 17 ’25, when Company’s Chief Financial Officer sold 11 for $1.11, making the entire transaction worth $12. This insider now owns 474,462 shares in total.
Esperion Therapeutics Inc (ESPR) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.06 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 25.51% per share during the next fiscal year.
Esperion Therapeutics Inc (NASDAQ: ESPR) Trading Performance Indicators
Take a look at Esperion Therapeutics Inc’s (ESPR) current performance indicators. Last quarter, stock had a quick ratio of 0.81. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 0.93.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.79, a number that is poised to hit -0.14 in the next quarter and is forecasted to reach -0.21 in one year’s time.
Technical Analysis of Esperion Therapeutics Inc (ESPR)
Let’s dig in a bit further. During the last 5-days, its volume was 2.77 million. That was inferior than the volume of 4.52 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 47.06%.
During the past 100 days, Esperion Therapeutics Inc’s (ESPR) raw stochastic average was set at 45.18%, which indicates a significant decrease from 81.48% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.0932 in the past 14 days, which was higher than the 0.0931 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.0353, while its 200-day Moving Average is $1.6890. However, in the short run, Esperion Therapeutics Inc’s stock first resistance to watch stands at $1.2600. Second resistance stands at $1.3000. The third major resistance level sits at $1.3650. If the price goes on to break the first support level at $1.1550, it is likely to go to the next support level at $1.0900. Assuming the price breaks the second support level, the third support level stands at $1.0500.
Esperion Therapeutics Inc (NASDAQ: ESPR) Key Stats
The company with the Market Capitalisation of 241.80 million has total of 198,199K Shares Outstanding. Its annual sales at the moment are 332,310 K in contrast with the sum of -51,750 K annual income. Company’s last quarter sales were recorded 65,000 K and last quarter income was -40,460 K.
